Bergamot extract and red yeast rice in reducing high cholesterol - what is known?
DOI:
https://doi.org/10.12775/QS.2024.19.54210Keywords
hypercholesterolemia, dyslipidemia, Citrus bergamiaAbstract
Obtaining optimal levels of lipoproteins and total cholesterol is one of the main goals for reducing cardiovascular risk. Many patients insist on changing their statin treatment to a nutraceutical such as Bergamot extract or red yeast rice extract, due to statin intolerance affecting some of them and increasing disinformation on statin side effects. This is why, interest in lipid-lowering ability of available nutraceuticals, is growing.
In our work, we tried to summarise what is known about nutraceuticals such as red yeast rice and bergamot extract and how they can be used in clinical practise.
We searched two databases such us Pubmed and Medline byusing the terms “bergamot”, ”red yeast rice”, “dyslipidaemia” and “hypercholesterolaemia”
Products containing red yeast rice and bergamot extract are dietary supplements which are sold over the counter. There is possibility that they can be seen as natural substances which significantly reduce cholesterol levels, however, they have weaker effect than strong statins. They cannot be replacement for them.
Red yeast rice is the leading substance. It can be used in patients with moderate hypercholesterolemia or can be combined with ezetimibe if statins are badly tolerated. There is no clear opinion of experts on bergamot due to lack of larger and longer studies.
As our article show it is crucial to conduct more scientific research on nutraceuticals especially Bergamot extract.
References
Civeira F, Arca M, Cenarro A, Hegele RA. A mechanism-based operational definition and classification of hypercholesterolemia. J Clin Lipidol. 2022;16(6):813-821. doi:10.1016/j.jacl.2022.09.006
Marcusa DP, Giugliano RP, Park JG, De Lemos JA, Cannon CP, Sabatine MS. Association of Baseline Low-Density Lipoprotein Cholesterol and Percentage Low-Density Lipoprotein Cholesterol Reduction With Statins, Ezetimibe, and PCSK9 Inhibition. JAMA Cardiol. 2020;6(5):582-586. doi:10.1001/JAMACARDIO.2020.6184
Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews. 2013;2017(5). doi:10.1002/14651858.CD004816.PUB5/INFORMATION/EN
Gencer B, Marston NA, Im KA, et al. Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. Lancet. 2020;396(10263):1637-1643. doi:10.1016/S0140-6736(20)32332-1
Thompson PD, Panza G, Zaleski A, Taylor B. Statin-Associated Side Effects. J Am Coll Cardiol. 2016;67(20):2395-2410. doi:10.1016/J.JACC.2016.02.071
Attardo S, Musumeci O, Velardo D, Toscano A. Statins Neuromuscular Adverse Effects. Int J Mol Sci. 2022;23(15). doi:10.3390/IJMS23158364
Ward NC, Watts GF, Eckel RH. Statin Toxicity: Mechanistic Insights and Clinical Implications. Circ Res. 2019;124(2):328-350. doi:10.1161/CIRCRESAHA.118.312782/ASSET/A896293C-CBD7-47CF-9A17-7B59BA09AC3E/ASSETS/IMAGES/LARGE/328FIG03.JPG
Nauman MC, Johnson JJ. Clinical application of bergamot (Citrus bergamia) for reducing high cholesterol and cardiovascular disease markers. Integr Food Nutr Metab. 2019;6(2). doi:10.15761/IFNM.1000249
Ferlazzo N, Visalli G, Smeriglio A, et al. Flavonoid Fraction of Orange and Bergamot Juices Protect Human Lung Epithelial Cells from Hydrogen Peroxide-Induced Oxidative Stress. Evid Based Complement Alternat Med. 2015;2015. doi:10.1155/2015/957031
Risitano R, Currò M, Cirmi S, et al. Flavonoid fraction of Bergamot juice reduces LPS-induced inflammatory response through SIRT1-mediated NF-κB inhibition in THP-1 monocytes. PLoS One. 2014;9(9). doi:10.1371/JOURNAL.PONE.0107431
Cappello AR, Dolce V, Iacopetta D, et al. Bergamot (Citrus bergamia Risso) Flavonoids and Their Potential Benefits in Human Hyperlipidemia and Atherosclerosis: an Overview. Mini-Reviews in Medicinal Chemistry. 2016;16(8):619-629. doi:10.2174/1389557515666150709110222
Kłosiewicz-Latoszek L, Cybulska B, Stoś K, Tyszko P. Hypolipaemic nutraceutics: red yeast rice and Armolipid, berberine and bergamot. Ann Agric Environ Med. 2021;28(1):81-88. doi:10.26444/AAEM/130629
Nogata Y, Sakamoto K, Shiratsuchi H, Ishii T, Yano M, Ohta H. Flavonoid composition of fruit tissues of citrus species. Biosci Biotechnol Biochem. 2006;70(1):178-192. doi:10.1271/BBB.70.178
Gattuso G, Barreca D, Gargiulli C, Leuzzi U, Caristi C. Flavonoid composition of Citrus juices. Molecules. 2007;12(8):1641-1673. doi:10.3390/12081641
Dugo P, Presti M Lo, Öhman M, Fazio A, Dugo G, Mondello L. Determination of flavonoids in citrus juices by micro-HPLC-ESI/MS. J Sep Sci. 2005;28(11):1149-1156. doi:10.1002/JSSC.200500053
Tranchida PQ, Presti M Lo, Costa R, Dugo P, Dugo G, Mondello L. High-throughput analysis of bergamot essential oil by fast solid-phase microextraction-capillary gas chromatography-flame ionization detection. J Chromatogr A. 2006;1103(1):162-165. doi:10.1016/J.CHROMA.2005.11.073
Arnaboldi L, Corsini A, Bellosta S. Artichoke and bergamot extracts: a new opportunity for the management of dyslipidemia and related risk factors. Minerva Med. 2022;113(1):141-157. doi:10.23736/S0026-4806.21.07950-7
Yu J, Wang L, Walzem RL, Miller EG, Pike LM, Patil BS. Antioxidant activity of citrus limonoids, flavonoids, and coumarins. J Agric Food Chem. 2005;53(6):2009-2014. doi:10.1021/JF0484632
Choe SC, Kim HS, Jeong TS, Bok SH, Park YB. Naringin has an antiatherogenic effect with the inhibition of intercellular adhesion molecule-1 in hypercholesterolemic rabbits. J Cardiovasc Pharmacol. 2001;38(6):947-955. doi:10.1097/00005344-200112000-00017
Mannucci C, Navarra M, Calapai F, Squeri R, Gangemi S, Calapai G. Clinical Pharmacology of Citrus bergamia: A Systematic Review. Phytotherapy Research. 2017;31(1):27-39. doi:10.1002/PTR.5734
Toth PP, Patti AM, Nikolic D, et al. Bergamot Reduces Plasma Lipids, Atherogenic Small Dense LDL, and Subclinical Atherosclerosis in Subjects with Moderate Hypercholesterolemia: A 6 Months Prospective Study. Front Pharmacol. 2016;6(JAN). doi:10.3389/FPHAR.2015.00299
Mollace V, Scicchitano M, Paone S, et al. Hypoglycemic and Hypolipemic Effects of a New Lecithin Formulation of Bergamot Polyphenolic Fraction: A Double Blind, Randomized, Placebo- Controlled Study. Endocr Metab Immune Disord Drug Targets. 2019;19(2):136-143. doi:10.2174/1871530319666181203151513
Lamiquiz-Moneo I, Giné-González J, Alisente S, et al. Effect of bergamot on lipid profile in humans: A systematic review. Crit Rev Food Sci Nutr. 2020;60(18):3133-3143. doi:10.1080/10408398.2019.1677554
Mollace V, Sacco I, Janda E, et al. Hypolipemic and hypoglycaemic activity of bergamot polyphenols: from animal models to human studies. Fitoterapia. 2011;82(3):309-316. doi:10.1016/J.FITOTE.2010.10.014
Babish JG, Dahlberg CJ, Ou JJ, et al. Synergistic in vitro antioxidant activity and observational clinical trial of F105, a phytochemical formulation including Citrus bergamia, in subjects with moderate cardiometabolic risk factors. Can J Physiol Pharmacol. 2016;94(12):1257-1266. doi:10.1139/CJPP-2016-0062
Osadnik T, Goławski M, Lewandowski P, et al. A network meta-analysis on the comparative effect of nutraceuticals on lipid profile in adults. Pharmacol Res. 2022;183:106402. doi:10.1016/J.PHRS.2022.106402
Sadeghi-dehsahraei H, Esmaeili Gouvarchin Ghaleh H, Mirnejad R, Parastouei K. The effect of bergamot (KoksalGarry) supplementation on lipid profiles: A systematic review and meta-analysis of randomized controlled trials. Phytother Res. 2022;36(12):4409-4424. doi:10.1002/PTR.7647
Miceli N, Mondello MR, Monforte MT, et al. Hypolipidemic effects of Citrus bergamia Risso et Poiteau juice in rats fed a hypercholesterolemic diet. J Agric Food Chem. 2007;55(26):10671-10677. doi:10.1021/JF071772I
Minamizuka T, Koshizaka M, Shoji M, et al. Low dose red yeast rice with monacolin K lowers LDL cholesterol and blood pressure in Japanese with mild dyslipidemia: A multicenter, randomized trial. Asia Pac J Clin Nutr. 2021;30(3):424-435. doi:10.6133/APJCN.202109_30(3).0009
Chen B, Huang X, Peng H, et al. Effectiveness and safety of red yeast rice predominated by monacolin K β-hydroxy acid form for hyperlipidemia treatment and management. J Tradit Chin Med. 2022;42(2):264-271. doi:10.19852/J.CNKI.JTCM.2022.02.007
Verhoeven V, Lopez Hartmann M, Remmen R, Wens J, Apers S, Van Royen P. Red yeast rice lowers cholesterol in physicians - a double blind, placebo controlled randomized trial. BMC Complement Altern Med. 2013;13:178. doi:10.1186/1472-6882-13-178
Bogsrud MP, Ose L, Langslet G, et al. HypoCol (red yeast rice) lowers plasma cholesterol - a randomized placebo controlled study. Scand Cardiovasc J. 2010;44(4):197-200. doi:10.3109/14017431003624123
Heinz T, Schuchardt JP, Möller K, Hadji P, Hahn A. Low daily dose of 3 mg monacolin K from RYR reduces the concentration of LDL-C in a randomized, placebo-controlled intervention. Nutrition Research. 2016;36(10):1162-1170. doi:10.1016/J.NUTRES.2016.07.005
Banach M, Bruckert E, Descamps OS, et al. The role of red yeast rice (RYR) supplementation in plasma cholesterol control: A review and expert opinion. Atheroscler Suppl. 2019;39:e1-e8. doi:10.1016/J.ATHEROSCLEROSISSUP.2019.08.023
Banach M, Patti AM, Giglio RV, et al. The Role of Nutraceuticals in Statin Intolerant Patients. J Am Coll Cardiol. 2018;72(1):96-118. doi:10.1016/J.JACC.2018.04.040
Cicero AFG, Fogacci F, Banach M. Red Yeast Rice for Hypercholesterolemia. Methodist Debakey Cardiovasc J. 2019;15(3):192. doi:10.14797/MDCJ-15-3-192
Brouwers J, Lennep JR van, Maas A. “Red yeast rice” as a cholesterol-lowering substance? Caution is warranted. Ned Tijdschr Geneeskd. 2016;160:D99. Accessed July 14, 2024. https://pure.eur.nl/en/publications/red-yeast-rice-as-a-cholesterol-lowering-substance-caution-is-war
Farkouh A, Baumgärtel C. Mini-review: medication safety of red yeast rice products. Int J Gen Med. 2019;12:167. doi:10.2147/IJGM.S202446
Ye P, Lu ZL, Du BM, et al. Effect of xuezhikang on cardiovascular events and mortality in elderly patients with a history of myocardial infarction: a subgroup analysis of elderly subjects from the China Coronary Secondary Prevention Study. J Am Geriatr Soc. 2007;55(7):1015-1022. doi:10.1111/J.1532-5415.2007.01230.X
Lu Z, Kou W, Du B, et al. Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol. 2008;101(12):1689-1693. doi:10.1016/J.AMJCARD.2008.02.056
Sungthong B, Yoothaekool C, Promphamorn S, Phimarn W. Efficacy of red yeast rice extract on myocardial infarction patients with borderline hypercholesterolemia: A meta-analysis of randomized controlled trials. Sci Rep. 2020;10(1). doi:10.1038/S41598-020-59796-5
Gerards MC, Terlou RJ, Yu H, Koks CHW, Gerdes VEA. Traditional Chinese lipid-lowering agent red yeast rice results in significant LDL reduction but safety is uncertain - a systematic review and meta-analysis. Atherosclerosis. 2015;240(2):415-423. doi:10.1016/J.ATHEROSCLEROSIS.2015.04.004
Fogacci F, Banach M, Mikhailidis DP, et al. Safety of red yeast rice supplementation: A systematic review and meta-analysis of randomized controlled trials. Pharmacol Res. 2019;143:1-16. doi:10.1016/J.PHRS.2019.02.028
Li P, Wang Q, Chen K, et al. Red Yeast Rice for Hyperlipidemia: A Meta-Analysis of 15 High-Quality Randomized Controlled Trials. Front Pharmacol. 2022;12. doi:10.3389/FPHAR.2021.819482
Cicero AFG, Fogacci F, Stoian AP, et al. Nutraceuticals in the Management of Dyslipidemia: Which, When, and for Whom? Could Nutraceuticals Help Low-Risk Individuals with Non-optimal Lipid Levels? Curr Atheroscler Rep. 2021;23(10). doi:10.1007/S11883-021-00955-Y
Penson PE, Banach M. The Role of Nutraceuticals in the Optimization of Lipid-Lowering Therapy in High-Risk Patients with Dyslipidaemia. Curr Atheroscler Rep. 2020;22(11). doi:10.1007/S11883-020-00887-Z
Banach M, Katsiki N, Latkovskis G, et al. Postmarketing nutrivigilance safety profile: a line of dietary food supplements containing red yeast rice for dyslipidemia. Arch Med Sci. 2021;17(4):856. doi:10.5114/AOMS/133716
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Justyna Składanek, Michał Leśkiewicz, Barbara Kopczyńska
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 106
Number of citations: 0